325 related articles for article (PubMed ID: 23450818)
1. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
3. Transient myeloproliferative syndrome/transient acute myeloid leukemia in a newborn with Down syndrome: a case report and literature review.
D'Angelo G; Merlo P
Lab Hematol; 2003; 9(1):38-41. PubMed ID: 12661826
[TBL] [Abstract][Full Text] [Related]
4. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
Ghannadan M; Wimazal F; Simonitsch I; Sperr WR; Mayerhofer M; Sillaber C; Hauswirth AW; Gadner H; Chott A; Horny HP; Lechner K; Valent P
Am J Clin Pathol; 2003 May; 119(5):663-71. PubMed ID: 12760284
[TBL] [Abstract][Full Text] [Related]
6. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
[TBL] [Abstract][Full Text] [Related]
7. [Acute myeloid leukemia in children with Down syndrome].
Creutzig U; Ritter J; Ludwig WD; Niemeyer C; Reinisch I; Stollmann-Gibbels B; Zimmermann M; Harbott J
Klin Padiatr; 1995; 207(4):136-44. PubMed ID: 7564143
[TBL] [Abstract][Full Text] [Related]
8. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis.
Karandikar NJ; Aquino DB; McKenna RW; Kroft SH
Am J Clin Pathol; 2001 Aug; 116(2):204-10. PubMed ID: 11488066
[TBL] [Abstract][Full Text] [Related]
9. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
[TBL] [Abstract][Full Text] [Related]
10. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
11. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
12. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
[TBL] [Abstract][Full Text] [Related]
13. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
14. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
15. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.
Kobayashi K; Usami I; Kubota M; Nishio T; Kakazu N
Cancer Genet Cytogenet; 2005 Apr; 158(2):184-7. PubMed ID: 15796967
[TBL] [Abstract][Full Text] [Related]
17. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
18. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.
Apollonsky N; Shende A; Ouansafi I; Brody J; Atlas M; Aygun B
J Pediatr Hematol Oncol; 2008 Nov; 30(11):860-4. PubMed ID: 18989165
[TBL] [Abstract][Full Text] [Related]
19. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
20. GATA1 mutations in acute leukemia in children with Down syndrome.
Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
